Is it all Trump's fault for wildly swinging the 'tariff club'? Pfizer: Uncertainty has hindered manufacturing and research and development investment.
① Pfizer CEO Albert Bourla stated that the uncertainty surrounding Trump's proposed pharmaceutical tariffs is hindering the company's manufacturing and R&D investments in the USA; ② Bourla emphasized that the company hopes to see "certainty," meaning clear tariffs or additional incentives, to increase investment in the USA.
Earnings Call Summary | Pfizer(PFE.US) Q1 2025 Earnings Conference
Pfizer Targets $7.7B in Operational Efficiency Savings by 2027, Highlights Strategic R&D Shifts
Viking Among Notable Gainers as Pfizer Raises Deal Prospects
Eli Lilly Set To Report Earnings As Investors Eye Weight Loss Drug Momentum
Pfizer Shares Are Trading Higher Following a Q1 EPS Beat. The Company Reaffirmed Guidance but Said It Is Trending Towards the Upper End of Its 2025 Adjusted Diluted EPS Guidance Range.
Dow Boosted by Honeywell, Sherwin-Williams While S&P and Nasdaq Seesaw
Sandoz Inks Agreement With Shanghai Henlius for Bristol Yervoy Biosimilar
Pfizer's Covid Windfall Shrinks, Expands Cost-Cutting Efforts
WeightWatchers Rises on Partnership With Eli Lilly to Enhance Zepbound Access
4 Stocks to Watch on Tuesday: KO, PFE, GM and UPS
Pfizer Hints at Acquisitions to Boost Obesity Pipeline After Trial Setback
Pfizer in Charts: Global Biopharma Business Revenue Down 23% Q/Q and 8% Y/Y in Q1
Prizer Says 'The Company's Reaffirmed Guidance Does Not Currently Include Any Potential Impact Related to Future Tariffs and Trade Policy Changes, Which We Are Unable to Predict at This Time.'
Pfizer Non-GAAP EPS of $0.92 Beats by $0.24, Revenue of $13.72B Misses by $370M
Merck to Build $1B Delaware Plant to Ensure Domestic Supply of Keytruda - Report
Nvidia, Johnson & Johnson, Hyundai, Toyota, SoftBank CEOs To Join Trump At White House As He Touts Investment Surge In First 100 Days: Report
Earnings Scheduled For April 29, 2025
Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline
Pfizer Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts